Literature DB >> 24375426

Performance of the timed "up & go" test in spinal muscular atrophy.

Sally Dunaway1, Jacqueline Montes, Carol Ewing Garber, Brendan Carr, Samantha S Kramer, Shirit Kamil-Rosenberg, Nancy Strauss, Douglas Sproule, Darryl C De Vivo.   

Abstract

INTRODUCTION: The timed "up & go" (TUG) test is a quick measure of balance and mobility. TUG scores correlate with clinical, functional, and strength assessment and decline linearly over time. Reliability and validity have not been tested in spinal muscular atrophy (SMA).
METHODS: Fifteen ambulatory SMA participants performed TUG testing and strength, functional, and clinical assessments. Intraclass correlation coefficients quantified test-retest reliability. Convergent validity was determined using Pearson correlation coefficients.
RESULTS: Test-retest reliability was excellent for all participants. TUG was associated significantly with total leg and knee flexor strength, as well as the Hammersmith Functional Motor Scale Expanded, the 10-meter walk/run, and 6-minute walk tests. TUG findings were not associated with knee extensor strength, pulmonary function, or fatigue.
CONCLUSIONS: In SMA, the TUG test is easily administered, reliable, and correlates with established outcome measures. TUG testing is a potentially useful outcome measure for clinical trials and a measure of disability in ambulatory patients with SMA.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  clinical trials; functional mobility; outcome measure; spinal muscular atrophy; timed “up & go” test

Mesh:

Year:  2014        PMID: 24375426     DOI: 10.1002/mus.24153

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

2.  Nusinersen Treatment in Adults With Spinal Muscular Atrophy.

Authors:  Tina Duong; Connie Wolford; Michael P McDermott; Chelsea E Macpherson; Amy Pasternak; Allan M Glanzman; William B Martens; Elizabeth Kichula; Basil T Darras; Darryl C De Vivo; Zarazuela Zolkipli-Cunningham; Richard S Finkel; Michael Zeineh; Max Wintermark; Jacinda Sampson; Katharine A Hagerman; Sally Dunaway Young; John W Day
Journal:  Neurol Clin Pract       Date:  2021-06

Review 3.  Physical exercise training for type 3 spinal muscular atrophy.

Authors:  Bart Bartels; Jacqueline Montes; W Ludo van der Pol; Janke F de Groot
Journal:  Cochrane Database Syst Rev       Date:  2019-03-01

Review 4.  Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.

Authors:  Rachel A Kennedy; Kate Carroll; Jennifer L McGinley; Kade L Paterson
Journal:  J Foot Ankle Res       Date:  2020-03-02       Impact factor: 2.303

5.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

6.  Quantitative gait assessment in children with 16p11.2 syndrome.

Authors:  Sylvie Goldman; Aston K McCullough; Sally Dunaway Young; Carly Mueller; Adrianna Stahl; Audrey Zoeller; Laurel Daniels Abbruzzese; Ashwini K Rao; Jacqueline Montes
Journal:  J Neurodev Disord       Date:  2019-10-27       Impact factor: 4.025

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.